[Cerebral manifestations in parablastic leukemia in childhood].
D000963:Antimetabolites / Q000009:adverse effects; D001927:Brain Diseases / Q000209:etiology* / Q000532:radiotherapy; D002241:Carbohydrates / Q000134:cerebrospinal fluid; D003585:Cell Biology; D002555:Cerebrospinal Fluid / Q000166:cytology; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007278:Injections, Spinal; D007938:Leukemia / Q000401:mortality; D007945:Leukemia, Lymphoid / Q000150:complications*; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D008297:Male; D008581:Meningitis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000627:therapeutic use; D013736:Testicular Neoplasms / Q000209:etiology
D000963:Antimetabolites; D002241:Carbohydrates; D002556:Cerebrospinal Fluid Proteins; D011241:Prednisone; D008727:Methotrexate
Zerebrale Manifestationen bei Parabastenleukämie im Kindesalter.